BR0318026A - Antìgenos recombinantes do vìrus da hepatite a, e, uso dos antìgenos - Google Patents

Antìgenos recombinantes do vìrus da hepatite a, e, uso dos antìgenos

Info

Publication number
BR0318026A
BR0318026A BR0318026-3A BR0318026A BR0318026A BR 0318026 A BR0318026 A BR 0318026A BR 0318026 A BR0318026 A BR 0318026A BR 0318026 A BR0318026 A BR 0318026A
Authority
BR
Brazil
Prior art keywords
antigens
hepatitis
virus
recombinant
hav
Prior art date
Application number
BR0318026-3A
Other languages
English (en)
Inventor
Alina Lopez Quesada
Beatriz Gonzalez Badillo
Guillermo Selman-Housein Sosa
Abel Hernandez Velasquez
Javier Rios Bacallao
Yamilka Rosabal Ayon
Marlen Perez Martinez
Licel Rodriguez Lay
Rolando Garcia Gonzalez
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Publication of BR0318026A publication Critical patent/BR0318026A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

"ANTìGENOS RECOMBINANTES DO VìRUS DA HEPATITE A, E, USO DOS ANTìGENOS". A invenção diz respeito a antígenos recombinantes do vírus da hepatite A obtidos em células de plantas. Mais especificamente, a invenção diz respeito à geração de construções genéticas baseadas em fragmentos modificados do genoma do vírus da hepatite A (HAV), com o uso da cepa M2, isolada em Cuba. As seq³ências de nucleotídeos dos referidos fragmentos fundidos a sinais de localização e de regularização apropriadas são expressos em plantas transgênicas, dando origem a antígenos recombinantes de HAV compreendendo pentâmeros e/ou invólucros vazios, capazes de gerar uma resposta imune.
BR0318026-3A 2003-01-31 2003-12-19 Antìgenos recombinantes do vìrus da hepatite a, e, uso dos antìgenos BR0318026A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20030031A CU23202A1 (es) 2003-01-31 2003-01-31 ANTIGENOS RECOMBINANTES DEL VIRUS DE LA HEPATITIS A OBTENIDOS EN CéLULAS VEGETALES
PCT/CU2003/000017 WO2004067747A1 (es) 2003-01-31 2003-12-19 Antigenos recombinantes del virus de la hepatitis a obtenidos en celulas vegetales

Publications (1)

Publication Number Publication Date
BR0318026A true BR0318026A (pt) 2005-12-06

Family

ID=40091669

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0318026-3A BR0318026A (pt) 2003-01-31 2003-12-19 Antìgenos recombinantes do vìrus da hepatite a, e, uso dos antìgenos

Country Status (14)

Country Link
US (1) US20060147469A1 (pt)
EP (1) EP1589111A1 (pt)
JP (1) JP2006514078A (pt)
KR (1) KR20050100365A (pt)
CN (1) CN1745174A (pt)
AR (1) AR042960A1 (pt)
AU (1) AU2003291913A1 (pt)
BR (1) BR0318026A (pt)
CA (1) CA2510482A1 (pt)
CU (1) CU23202A1 (pt)
MX (1) MXPA05008221A (pt)
RU (1) RU2005127340A (pt)
WO (1) WO2004067747A1 (pt)
ZA (1) ZA200505187B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2615372A1 (en) * 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
KR101012830B1 (ko) * 2008-04-25 2011-02-10 메디칸(주) 신규 ａ형 간염 바이러스의 항원 유전자 및 상기 유전자로형질전환된 식물체

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516630A (en) * 1983-09-30 1996-05-14 The United States Of America As Represented By The Department Of Health And Human Services Methods of detecting hepatitis A virus
JPS61500053A (ja) * 1983-09-30 1986-01-16 マサチユ−セツツ　インステイチユ−ト　オブ　テクノロジ− Ａ肝炎ウィルス配列順を表すｃＤＮＡの生成
US4614793A (en) * 1983-10-14 1986-09-30 Merck & Co., Inc. Hepatitis A--subunit antigen
SU1469856A1 (ru) * 1986-07-31 1990-09-30 Институт биоорганической химии им.М.М.Шемякина Способ конструировани рекомбинантной плазмидной ДНК, кодирующей синтез полипептидных субстанций против гепатита А
US5294548A (en) * 1990-04-02 1994-03-15 American Biogenetic Sciences, Inc Recombianant Hepatitis a virus
US5612487A (en) * 1991-08-26 1997-03-18 Edible Vaccines, Inc. Anti-viral vaccines expressed in plants
CN100410268C (zh) * 1998-12-23 2008-08-13 博伊斯汤普生植物研究所 免疫原性的乙型肝炎表面抗原在转基因植物中的表达
US6368602B1 (en) * 2000-06-16 2002-04-09 Hadasit Medical Research Services And Development Ltd Mucosal immunization against hepatitis A virus (HAV) through rectal administration of HAV vaccine

Also Published As

Publication number Publication date
CN1745174A (zh) 2006-03-08
US20060147469A1 (en) 2006-07-06
KR20050100365A (ko) 2005-10-18
CA2510482A1 (en) 2004-08-12
AU2003291913A1 (en) 2004-08-23
ZA200505187B (en) 2006-04-26
EP1589111A1 (en) 2005-10-26
CU23202A1 (es) 2007-05-18
MXPA05008221A (es) 2005-10-05
WO2004067747A1 (es) 2004-08-12
JP2006514078A (ja) 2006-04-27
AR042960A1 (es) 2005-07-13
RU2005127340A (ru) 2006-03-10

Similar Documents

Publication Publication Date Title
Levitskaya et al. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein–Barr virus nuclear antigen 1
EP1385370A4 (en) ANTIMICROBIAL POLYPEPTIDES AND USES THEREOF
DK0941318T5 (da) Håndvægtformede konstruerede ekspressionssystemer til genterapi
Dixon et al. Nucleotide sequence of a 55 kbp region from the right end of the genome of a pathogenic African swine fever virus isolate (Malawi LIL20/1)
ES2285832T3 (es) Complejo de peptido antigenico-proteina de choque termico modificada.
DE69734882D1 (de) Dna immunisierung gegen chlamydia infektion
BRPI0309631A8 (pt) vacina tetravalente da dengue contendo uma trivial deleção de 30 nucleotídeos na utr-31' dos tipos de dengue 1,2,3 e 4, ou de vírus antigênicos quiméricos da dengue 1,2,3 e 4
AU6871398A (en) Method for enhancing expression of a foreign or endogenous gene product in pla nts
HUP9802217A2 (hu) Rekombináns MVA-vírus és alkalmazása
Hrabáková et al. Phomopsis longicolla RNA virus 1–Novel virus at the edge of myco-and plant viruses
DK1425404T3 (da) Vaccinia-MVA-E3L-mutanter og anvendelse deraf
ATE358135T1 (de) Phagen-abhängige superproduktion biologisch aktiver proteine und peptide
CY1106570T1 (el) Σταθερες, εξασθενημενες μεταλλαγμενες μορφες ιου λυσσας και ζωντανια εμβολια αυτων
BR0318026A (pt) Antìgenos recombinantes do vìrus da hepatite a, e, uso dos antìgenos
ATE494377T1 (de) Vakzine gegen ipnv die aus hefezellen isoliert werden
CU23245A1 (es) CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS
Lyons et al. Effect of natural sequence variation at the H-2Ld-restricted CD8+ T cell epitope of the murine cytomegalovirus ie1-encoded pp89 on T cell recognition
Wesley et al. The coat protein of Indian peanut clump virus: relationships with other furoviruses and with barley stripe mosaic virus
ATE453708T1 (de) Impfstoff gegen west nile virus
AR123206A1 (es) Terapia génica
BR0010222A (pt) Vetores de expressão viral
DE60019411D1 (de) Phage-abhängige superproduktion von biologisch aktiven proteinen und peptiden
PT1383796E (pt) Estirpe neurovirulenta do vírus do nilo ocidental e as suas aplicações
ES2367245T8 (es) Virus recombinante que expresa adn foráneo que codifica cd80 felino, cd28 felino, ctla-4felino o cd86 felino y usos del mismo.
Hassan et al. 155R is a novel structural protein of bovine adenovirus type 3, but it is not essential for virus replication

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]